Kineta (KA) Company Sales Volume

The sales dynamics chart for Kineta, Inc. (KA) is volatile due to expectations surrounding VISTA inhibitors and the potential for acquisition by a pharma behemoth. However, financial stability relies on the success of combating immunosuppression and the influx of investments. Currently, R&D has stalled due to a funding shortage, shifting the focus toward patents. The current metric is 0.00, which allows for a real-time assessment of the actual capital inflow into the business.

KA Kineta Bio: Company Sales in the range 04/28/2023 - 09/28/2024

Comprehensive metric breakdowns and analytics for Kineta (KA)

- price and consensus price forecast:

Stock Price Kineta Corp|KA - Price Target Chart

- market capitalization details:

Market Capitalization Kineta, Inc.|KA - Total Company Value

- issuer book value statistics:

Net Asset Value per Share Kineta|KA - Company Net Assets|Market Value to Equity Ratio kinetabio.com|KA - Cumulative Company Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

KA - Company Net Income|Forward Earnings Kineta, Inc.|KA - Price to Earnings Ratio|Projected Price to Earnings Ratio kinetabio.com|KA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Kineta, Inc.|KA - Operating profit EBITDA|Net earnings per share for the last four quarters Kineta|KA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months kinetabio.com|KA - Earnings growth in current year|Expected net earnings per share growth next year Kineta, Inc.

- issuer revenue and sales details:

KA - Company Sales|Company Projected Revenue Volume Kineta Corp|KA - P/S Multiple|Forward P/S Multiple Kineta, Inc.

Summary company analysis:KA (Kineta Corp)

A comparative asset analysis requires an assessment of actual cash inflows, where this metric measures daily sales intensity to decouple fundamental growth from market speculation. Amidst a staffing crisis and a freeze on development at Kineta, Inc. (KA), the company's sales agility becomes a key indicator of business viability, demonstrating the ability of a minimal scientific core to generate revenue despite an acute liquidity shortage.

Analysis of competing companies